Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Finished Goods (2020 - 2026)

Maxcyte has reported Finished Goods over the past 6 years, most recently at $3.2 million for Q4 2025.

  • Quarterly Finished Goods fell 18.97% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, down 18.97% year-over-year, with the annual reading at $3.2 million for FY2025, 18.97% down from the prior year.
  • Finished Goods was $3.2 million for Q4 2025 at Maxcyte, down from $3.3 million in the prior quarter.
  • Over five years, Finished Goods peaked at $6.0 million in Q1 2024 and troughed at $2.3 million in Q2 2021.
  • The 5-year median for Finished Goods is $3.5 million (2025), against an average of $3.8 million.
  • Year-over-year, Finished Goods soared 121.46% in 2023 and then tumbled 40.19% in 2025.
  • A 5-year view of Finished Goods shows it stood at $2.5 million in 2021, then increased by 16.25% to $2.9 million in 2022, then soared by 103.99% to $6.0 million in 2023, then plummeted by 34.3% to $3.9 million in 2024, then dropped by 18.97% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Finished Goods are $3.2 million (Q4 2025), $3.3 million (Q3 2025), and $3.5 million (Q2 2025).